Video

Dr. Raez on the KEYNOTE-407 Trial in Squamous NSCLC

Luis E. Raez, MD, discusses the impact of the KEYNOTE-407 trial in squamous non–small cell lung cancer.

Luis E. Raez, MD, medical director and chief scientific officer of Memorial Cancer Institute, Memorial Healthcare System, discusses the impact of the KEYNOTE-407 trial in squamous non—small cell lung cancer (NSCLC).

For many years, squamous NSCLC has been behind in drug development because agents, such as pemetrexed and bevacizumab (Avastin), did not have indications for squamous cell carcinoma, explains Raez.

However, the KEYNOTE-407 study shifted the field when it showed that using pembrolizumab (Keytruda) with carboplatin and nab-paclitaxel (Abraxane) or paclitaxel as a frontline therapy for patients with squamous NSCLC improved disease-free survival and overall survival, concludes Raez.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center